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Background: Nuclear receptor 4A2 (NR4A2) is an orphan nuclear receptor and constitutively active transcription
factor expressed at elevated levels in inflamed joint tissues from patients with arthritis. Inflammatory mediators
rapidly and potently induce NR4A2 expression in resident joint cells and infiltrating immune cells. This receptor
promotes synovial hyperplasia by increasing proliferation of synoviocytes and inducing transcription of matrix
degrading enzymes and pro-inflammatory mediators. In order to further elucidate the molecular mechanisms of
NR4A2, we conducted a gene expression screen to identify novel transcriptional targets of NR4A2 that may contribute
to arthritis progression.
Methods: NR4A2 was over-expressed in human synoviocytes by lentiviral transduction and gene expression changes
were measured using qPCR arrays specific for inflammation, proliferation, adhesion, and migration pathways. Subsequent
analysis focused on the most potently induced gene prolactin (PRL). Messenger RNA levels of PRL and PRL receptor
(PRL-R) were measured by RT-qPCR and protein levels were measured by ELISA. PRL promoter studies were conducted
in synoviocytes transiently transfected with NR4A2 and PRL reporter constructs. Molecular responses to PRL in
synoviocytes were addressed using qPCR arrays specific for JAK/STAT signaling pathways.
Results: PRL was the most potently induced gene on the qPCR arrays, exhibiting a 68-fold increase in response
to ectopic NR4A2. This gene encodes an immunomodulatory peptide hormone with roles in autoimmune diseases and
inflammation. Induction of PRL mRNA and secreted protein by NR4A2 was confirmed in subsequent experiments, with
increases of 300-fold and 18-fold respectively. Depletion of endogenous NR4A receptors with shRNA reduced basal and
PGE2-induced PRL levels by 95%. At the transcriptional level, NR4A2 requires a functional DNA binding domain
to transactivate the distal PRL promoter. Deletional analysis indicates that NR4A2 targets a region of the distal
PRL promoter spanning −270 to -32 bp. In synoviocytes, recombinant PRL regulates several genes involved in
inflammation, proliferation, and cell survival, suggesting that NR4A2 induced PRL may also impact these pathways and
contribute to arthritis progression.
Conclusions: These results provide the first evidence for transcriptional regulation of the immunomodulatory peptide
hormone PRL by NR4A2 in synoviocytes, and highlight a novel molecular pathway in inflammatory arthritis.
Keywords: Orphan nuclear receptor, Transcription, Prolactin, Arthritis, Synoviocytes, Promoter* Correspondence: kmix@loyno.edu
Department of Biological Sciences, Loyola University New Orleans, New
Orleans, Louisiana 70118, USA
© 2015 McCoy et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
McCoy et al. Journal of Inflammation  (2015) 12:13 Page 2 of 11Background
Inflammatory arthritis is driven by pro-inflammatory
mediators such as tumor necrosis factor-α (TNF-α) and
prostaglandin E2 (PGE2) that induce synovial hyperplasia
and trigger the erosion of cartilage and bone. During
the progression of arthritis, fibroblast-like synoviocytes
transform into aggressive cells that proliferate rapidly,
grow in an anchorage-independent manner, and invade
adjacent cartilage and bone [1]. At the molecular level,
transformed synoviocytes exhibit altered gene expression
profiles that reflect an increased capacity to degrade
extracellular matrix, promote inflammation, and stimu-
late angiogenesis [2]. These processes are tightly con-
trolled by transcription factors such as nuclear factor
kappa B (NFκB), cAMP response element binding
(CREB), c-Myc, and p53 [3-6]. In order to develop in-
novative strategies to reduce inflammation and preserve
joint integrity in patients with arthritis, it is important to
further elucidate the transcriptional networks and signal-
ing pathways active in arthritis.
The orphan nuclear receptor 4A2 (NR4A2/NURR1,
nuclear receptor related-1) has recently emerged as a
novel transcription factor with regulatory roles in in-
flammatory arthritis [7-13]. In contrast to most mem-
bers of the nuclear receptor super-family, NR4A2 is a
ligand-independent transcription factor whose activity is
tightly controlled at the level of expression and post-
translational modification [14]. NR4A2 is over-expressed
in inflamed synovial tissues and cartilage from patients
with rheumatoid arthritis (RA), osteoarthritis (OA), and
psoriatic arthritis (PsA), and NR4A2 is the most highly
expressed member of the NR4A receptor family in these
tissues [7-12]. Inflammatory cytokines and prostaglan-
dins rapidly and potently induce the nuclear expression
of NR4A2 in synoviocytes, chondrocytes, endothelial
cells, and immune cells [7,9,11,15]. While the molecular
functions of NR4A2 are not yet fully understood,
NR4A2 may serve as a viable drug target to regulate in-
flammatory pathways. In fact, conventional therapies such
as methotrexate, dexamethasone, and 6-mercaptopurine
can modulate NR4A2 expression and activity [8,11,16],
suggesting that some of the clinical benefits of these
agents may be mediated through effects on NR4A2. Fur-
thermore, novel small molecules that specifically target
NR4A2 may provide new strategies to treat inflammatory
arthritis [17].
We have recently demonstrated that NR4A2 promotes
synovial hyperplasia by increasing synoviocyte prolife-
ration, anchorage-independent growth, and invasion
through type II collagen [10]. In line with these cellular
changes, NR4A2 induces transcription of the cartilage
degrading enzyme, MMP-13, and decreases expression
of the tissue inhibitor of MMPs, TIMP-2 [10]. Additional
transcriptional targets of NR4A2 in synoviocytes includeIL-8, amphiregulin, and Kit ligand [13,18], indicating
that NR4A2 converges on transcriptional pathways that
control cell recruitment, proliferation, and tissue degrad-
ation. However, the transcriptional mechanisms of
NR4A2 have not been fully elucidated, and this receptor
likely regulates several genes that contribute to inflam-
mation and joint degradation in arthritis.
In this study, we conducted a gene expression screen
to identify novel transcriptional targets of NR4A2 that
may contribute to disease progression. Interestingly, the
immunomodulatory peptide hormone prolactin (PRL)
emerged as the most potently induced gene among a
panel of genes associated with inflammation, prolife-
ration, adhesion, and migration. While PRL has funda-
mental roles in reproduction and development, this
pleiotropic hormone also contributes to autoimmune
diseases and inflammation [19]. In patients with RA, ele-
vated levels of PRL correlate with disease activity and
structural damage [19-21]. Furthermore, reducing sys-
temic PRL levels with the dopamine agonist bromocrip-
tine has beneficial effects in patients with RA and in
animal models of disease [22]. Given the clinical links
between PRL levels and RA, we were intrigued by the
possibility that NR4A2 could be a potent regulator of
this immunomodulatory hormone.
Circulating PRL is largely derived from the anterior
pituitary gland, however it is also produced locally in in-
flamed joints. Synoviocytes, chondrocytes, and infiltrat-
ing immune cells synthesize PRL and these cells may
contribute to elevated levels of PRL in synovial fluid
from patients with RA [20,23-26]. PRL regulates syno-
viocyte proliferation, chondrocyte survival, and the
expression of MMPs and inflammatory cytokines by
engaging cell surface PRL receptors and activating intra-
cellular JAK/STAT signaling pathways [23,25,27]. The
transcriptional mechanisms supporting PRL synthesis
within inflamed joints are largely unexplored and we hy-
pothesized that NR4A2 may serve as a critical transcrip-
tion factor involved in this process.
After identifying PRL as a putative NR4A2 target gene,
we confirmed that NR4A2 potently induces PRL mRNA
and protein expression in human synoviocytes. Deple-
tion of the NR4A receptors by shRNA abrogates PGE2-
induced PRL expression, suggesting that these receptors
are critical for PRL synthesis. At the transcriptional level,
NR4A2 targets the proximal region of the distal PRL
promoter through a mechanism that requires DNA
binding. Recombinant PRL regulates gene expression
pathways that control inflammation, proliferation, and
cell survival in synoviocytes, suggesting that NR4A2-
induced PRL may elicit similar autocrine responses that
may subsequently impact arthritis progression. Our
results provide the first evidence for transcriptional
regulation of PRL by the orphan receptor NR4A2 in




K4IM normal human synoviocytes were cultured in
RPMI 1640 medium with 10% FBS as described previ-
ously [7,28]. Stable NR4A-depleted K4IM cells, kindly
provided by Dr. Evelyn Murphy (University College
Dublin), were generated by lentiviral transduction of
control scrambled short hairpin RNA (shRNA) and
shRNA specific for NR4A1, NR4A2, and NR4A3 recep-
tors [10]. Treatments were conducted in serum-free
RPMI medium. Human fibroblast-like synoviocytes (HFLS)
derived from normal and RA synovial tissues were ob-
tained from Cell Applications, Inc. HFLS were cultured in
synoviocyte growth medium and transferred to basal
medium for treatments (Cell Applications, Inc.). PGE2
(Sigma-Aldrich) was used at a final concentration of
1 μM in all experiments. Recombinant human TNF-α
(rhTNF-α, Sigma-Aldrich) was used at a final concentra-
tion of 10 ng/mL and rhPRL (R & D Systems) was used
at concentrations ranging from 10 ng/mL to 1 μg/mL.
Cell proliferation and viability was measured using an
MTT based non-radioactive assay (Promega).
Lentiviral transductions
Lentiviral particles containing empty vector control or
CMV-NR4A2 cDNA were produced in 293FT cells using
the ViraPower Lentiviral Expression System (Invitrogen).
Plasmids (pLenti-CMV, pLenti-CMV-hNR4A2) were
kindly provided by Dr. C.J.M de Vries (University of
Amsterdam). HFLS and K4IM cells were cultured in
growth media as described above to 50% confluence in 6
well plates. Cells were transduced in a total volume of
1 mL consisting of a 50:50 mix of growth media and fil-
tered lentiviral particles. Following a 12-hour incubation
with lentiviral particles, cells were washed and trans-
ferred to serum free media for 48 hours.
RNA extraction, reverse transcription, and PCR
Total RNA from synoviocytes was isolated at time-
points indicated in figure legends using TRIzol reagent
(Sigma-Aldrich). RNA was reverse-transcribed into cDNA
using iScript Select cDNA synthesis kit with an oligo-dT
primer (Bio-Rad). Standard qPCR was conducted using iQ
Super Mix (Bio-Rad), TaqMan primers and probes
(Life Technologies), and a Bio-Rad CFX96 qPCR ma-
chine. Relative expression levels were calculated using
the 2-ddCt method, normalizing to GAPDH. TaqMan
Human Angiogenesis Fast Arrays were conducted in a
96-well format using TaqMan Universal Master Mix II
(Life Technologies) and plates were run in an Applied Bio-
systems StepOnePlus 7500 Fast machine. Gene expressiondata was normalized to four housekeeping genes (18S,
GAPDH, HPRT1, GUSB) and relative quantification ana-
lysis was conducted using DataAssist software (Applied
Biosystems). Human JAK/STAT Signaling Pathway RT2
Arrays were conducted in a 96-well format using SYBR
Green reagents (Qiagen). Gene expression data was nor-
malized to three housekeeping genes (B2M, GAPDH,
RPLP0) and relative quantification analysis was conducted
using web-based PCR Array Data Analysis software
(SABiosciences). Standard RT-PCR was used to detect the
presence of exon 1A in PRL mRNA using primers in exon
1A and exon 2 described previously [29]. GAPDH was
used as a housekeeping control. PCR products were sepa-
rated on a 2% agarose 1xTAE gel, stained with ethidium
bromide, and images were collected with a Gel Doc system
(BioRad).
ELISA
Conditioned media from K4IM transduction experi-
ments were collected and stored at −80°C. Secreted PRL
in 100 μl of each sample was quantified in triplicate
using the DuoSet human PRL ELISA kit (R&D Systems).
A standard curve was generated using rhPRL.
Transfections
K4IM cells were transiently transfected in triplicate in
24 well plates using Geneporter 3000 reagents in 10%
FBS RPMI 1640 media (DNA Therapy Systems). Human
distal PRL promoter sequences (−3000, −270, and
-32 bp) were cloned into pGL3-Basic and kindly pro-
vided by Dr. Birgit Gellersen (University of Hamburg)
[30,31]. Cells were co-transfected with control CMV-β-
galactosidase, CMX-NR4A2 (gift from Dr. Thomas
Perlmann, Karolinska Institute), or CMX-NR4A2 C283G
DNA binding domain mutant [9]. Cells were transferred
to serum-free media 12 hours post-transfection and
whole cell extracts were collected 24 hours later in re-
porter lysis buffer (Promega). Luciferase assay reagent
(Promega) was combined with a 20 μl sample of each
extract and luminescence was measured on a Promega
GloMax 20/20 luminometer. Transfection experiments
were repeated at least three times in triplicate and con-
sistent results were obtained.
Statistical analysis
Prism software was used to compute the Student’s t-test
for all gene expression and transfection data. Results are
presented as the mean +/− standard deviation values.
Results
Previous studies have demonstrated that NR4A2 is over-
expressed in inflamed synovial tissues from patients with
RA and PsA, and inflammatory mediators potently induce
NR4A2 expression in primary synoviocytes [8,10-13]. To
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cytes, NR4A2 was ectopically expressed in the normal hu-
man synoviocyte cell line, K4IM. This cell line has been
used to study synoviocyte responses to inflammation and
NR4A2 expression patterns are consistent with those ob-
served in primary human synoviocytes [10,13,18,28]. The
related receptors NR4A1 and NR4A3 are expressed at
lower levels in this cell line [10]. K4IM cells were trans-
duced with an NR4A2 expression vector, and NR4A2
mRNA levels increased 350-fold after 48 hours (Figure 1A,
p < 0.001). These levels are comparable to endogenous
levels of NR4A2 induced by inflammatory cytokines
[10,13]. We have previously demonstrated that ectopically
expressed NR4A2 protein localizes to the nucleus where it
functions as a constitutively active transcription factor
[9,13]. To identify potential transcriptional targets of
NR4A2, cDNA from control and NR4A2 transduced cells






























Fold induction by NR4A2
Figure 1 NR4A2 induces expression of genes involved in
synovial hyperplasia and inflammation. A. K4IM human
synoviocytes were transduced in triplicate with lentiviral particles
containing control empty or CMV-NR4A2 expression vectors. RNA
was harvested after 48 hours and NR4A2 expression was measured
by RT-qPCR using GAPDH as a control. ***p < 0.001. B. Pooled triplicate
cDNA from the same experiment was analyzed on TaqMan Human
Angiogenesis qPCR arrays. Gene expression data was normalized to 4
housekeeping genes and the genes most highly induced by NR4A2
are displayed.genes involved in inflammation, cell proliferation, adhe-
sion, and migration were surveyed (Additional file 1:
Table S1). NR4A2 over-expression did not alter the
expression of most genes detected on the arrays, in-
dicating that this receptor does not have a global
transcriptional effect. However, NR4A2 induced a
subset of eight genes by 4-fold or more (Figure 1B).
PRL was the most potently induced gene, with NR4A2
upregulating its expression by 68-fold. IL-8 was induced
4-fold, consistent with reports indicating that this che-
mokine is transcriptionally regulated by NR4A2 [13,18].
Additional genes induced by NR4A2 include fibulin 5,
TEK, follistatin, angiopoietin-1, cadherin 5, and integrin
β3. Interestingly, some of these genes have also been de-
tected in inflamed joints and they modulate synoviocyte
function, angiogenesis, and inflammation [32,33].
Since PRL was identified as the most highly induced
gene on the qPCR arrays, and this peptide hormone has
immunomodulatory roles in inflammatory joint diseases
[19], we focused on PRL as a potential target gene of
NR4A2. Induction of PRL mRNA was confirmed in sub-
sequent experiments, with a potent 300-fold increase in
response to ectopic NR4A2 in K4IM cells (Figure 2A,
p < 0.005). Furthermore, levels of secreted PRL pro-
tein in conditioned media from these cells increased
18-fold, from 27 to 484 pg/mL (Figure 2B, p < 0.005).
Regulation of PRL was also confirmed in primary human
fibroblast-like synoviocytes (HFLS) derived from normal
synovial tissue, where mRNA levels were induced 27-fold
by ectopic NR4A2 (Figure 2C, p < 0.01).
To address the impact of endogenous NR4A2 on PRL
expression, K4IM cells were treated with a potent inducer
of NR4A2 expression, PGE2 [7]. NR4A2 mRNA was in-
duced 14-fold after 1 hour of stimulation, and levels
returned to baseline by 24 hours (Figure 3A, p < 0.05). In
contrast, PRL exhibited a delayed expression pattern in re-
sponse to PGE2, with mRNA levels increasing from 4-fold
to 43-fold in 48 hours (Figure 3B, p < 0.005). These kinetics
suggest that the early induction of NR4A2 may subse-
quently contribute to PRL induction. To test this, K4IM
cells were stably transfected with shRNA specific for
NR4A1-3 or a scrambled control. NR4A2 levels were re-
duced by 85% in response to NR4A1-3 shRNA (Figure 3C,
p < 0.005). In turn, basal and PGE2-induced PRL levels
were reduced by 95% (Figure 3D, p < 0.005), indicating that
the NR4A receptors are required for PRL expression.
Since NR4A2 is a constitutively active transcription
factor, we hypothesized that NR4A2 induces PRL expres-
sion at the level of transcription. PRL is regulated by two
distinct promoters located on human chromosome 6.
The proximal promoter confers expression in the pituit-
ary, while the distal promoter, located approximately
5 kb upstream of the start-site of transcription, typic-






























































Figure 2 NR4A2 induces PRL mRNA and protein secretion. A. K4IM human synoviocytes were transduced in triplicate with lentiviral particles
containing control empty or CMV-NR4A2 expression vectors. RNA was harvested after 48 hours and PRL expression was measured by RT-qPCR
using GAPDH as a control. **p < 0.005. B. Conditioned media from transduced K4IM cells was collected after 48 hours and secreted PRL was
measured by ELISA. **p < 0.005. C. HFLS derived from normal synovial tissue were transduced in triplicate with lentiviral particles containing
control empty or CMV-NR4A2 expression vectors. RNA was harvested after 48 hours and PRL expression was measured by RT-qPCR using
GAPDH as a control. *p < 0.01.
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incorporation of an additional noncoding exon 1A in
the PRL transcript, while transcripts derived from the
proximal promoter lack this sequence [35]. To determine
which promoter is activated by NR4A2 in synoviocytes,
we conducted RT-PCR with primers specific for exon 1A
and exon 2 of PRL [29]. A product with the expected size
of 275 bp was detected in cDNA from K4IM cells trans-
duced with NR4A2, confirming the presence of exon 1A
in PRL transcripts (Figure 4A). This finding indicates that
NR4A2-induced PRL is in fact derived from the distal pro-
moter. To extend this observation, transient transfections
were conducted with a distal PRL promoter luciferase
reporter (−3000 bp). Co-transfection of an NR4A2 expres-
sion vector potently induced transactivation of this pro-
moter (Figure 4B, p < 0.005), confirming that NR4A2
targets the distal promoter to increase PRL transcription.
NR4A2 can activate transcription through direct binding
to NR4A-binding response elements (NBRE: AAAGGTCA)
in the promoters of target genes [14]. However, analysis of
the PRL promoter sequence did not identify any putativeNBRE sites, suggesting that NR4A2 may interact with novel
cis-elements to induce PRL expression. Deletional analysis
of the distal PRL promoter was conducted to identify the
site (s) targeted by NR4A2. The full-length -3000 bp and
truncated -270 bp promoters are induced by NR4A2 to
a similar extent (Figure 5A, p < 0.005), suggesting that
this intervening sequence is not required for NR4A2
activity. In contrast, NR4A2 failed to transactivate
the -32 bp promoter, indicating that NR4A2 cis-elements
are absent in this truncated promoter. These results sug-
gest that NR4A2 transactivates the PRL promoter by tar-
geting sequences in the region spanning −32 to -270 bp.
Furthermore, a well-characterized point mutation in the
DNA binding domain of NR4A2, C283G [9], abrogated
transactivation of the promoter, suggesting that direct
DNA binding is required for PRL transcription (Figure 5B).
Taken together, we have identified PRL as a novel tran-
scriptional target of NR4A2 in synoviocytes and have de-
termined that NR4A2 targets the distal promoter region
spanning −32 to 270 bp through a mechanism that re-
quires DNA binding.
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Figure 3 NR4A receptors are required for PGE2 induction of PRL. A. Triplicate wells of K4IM synoviocytes were left untreated or stimulated
with PGE2 (1 μM) in serum-free media for the times indicated. NR4A2 expression levels were measured by RT-qPCR. *p < 0.05. B. PRL expression
levels were measured by RT-qPCR in the same experiment. *p < 0.05, **p < 0.005. C. Scrambled shRNA or NR4A1-3 shRNA transduced K4IM
synoviocytes were left untreated or treated with PGE2 for one hour. NR4A2 expression levels were measured by RT-qPCR. **p < 0.005.
D. Scrambled shRNA or NR4A1-3 shRNA transduced K4IM synoviocytes were left untreated or treated with PGE2 for 24 hours. PRL expression
levels were measured by RT-qPCR. **p < 0.005.
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pression in synoviocytes. Extracellular PRL binds to cell
surface PRL receptors (PRL-R) and activates JAK/STAT
signaling pathways. To address potential autocrine ef-
fects of PRL on synoviocytes, we first documented the
expression levels of PRL-R. K4IM synoviocytes express
detectable levels of PRL-R by RT-qPCR, suggesting that
this receptor system is intact. Furthermore, TNF-α po-
tently induces PRL-R expression by 15-fold, while PGE2
has no effect (Figure 6A), suggesting that inflammatory
mediators may differentially modulate PRL signaling.Previous studies suggest that PRL can regulate prolifera-
tion and survival of RA synovial cells and chondrocytes
[23,25,27], thus we investigated the impact of PRL on
these processes. However, we did not observe any effects
on the proliferation or viability of K4IM synoviocytes or
primary HFLS derived from RA synovial tissue in re-
sponse to recombinant human PRL (Additional file 2:
Figure S1).
To further address the impact of PRL on synovio-
cytes, we surveyed global gene expression changes




















Figure 4 NR4A2 transactivates the distal PRL promoter in
synoviocytes. A. RT-PCR was conducted with primers specific for
exon 1A and exon 2 of PRL or GAPDH and products were resolved
on an agarose gel. PRL primers yielded the expected product size of
275 bp, indicating the presence of exon 1A in PRL transcripts.
GAPDH specific primers produced the expected product size of
451 bp. Lanes 1–3 contained the following PCR templates: cDNA
from control transduced K4IM cells, cDNA from NR4A2 transduced
K4IM cells, and negative control. B. K4IM synoviocytes were transiently
transfected in triplicate with a distal PRL promoter (−3000 bp) luciferase
reporter and control or NR4A2 expression vectors as indicated.
Relative luciferase units (RLUs) were measured in cell lysates 48 hours



























Figure 5 DNA-binding domain of NR4A2 is required for
transactivation of PRL promoter. A. K4IM synoviocytes were
transiently transfected in triplicate with distal PRL promoter
luciferase reporters (−3000 bp, −270 bp, −32 bp) and control or
NR4A2 expression vectors as indicated. Relative luciferase units
(RLUs) were measured in cell lysates 48 hours post-transfection.
**p < 0.005. B. K4IM synoviocytes were transiently transfected in
triplicate with a distal PRL promoter (−270 bp) luciferase reporter and
control, NR4A2, or NR4A2 C283G (DNA binding domain mutant)
expression vectors as indicated. Relative luciferase units (RLUs) were
measured in cell lysates 48 hours post-transfection. *p < 0.05.
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signaling cascades are activated by PRL, and the se-
lected qPCR arrays contain genes that are known tar-
gets of PRL. A group of 11 genes were significantly
altered by rhPRL treatment (Figure 6B). Importantly,
Akt1, IRF1, and SOCS-1 are transcriptional targets of
PRL [36-38], and we confirmed a 2-fold increase in
their expression. In addition, many of the PRL respon-
sive genes identified contribute to inflammation, prolif-
eration, and cell survival in inflamed joints [39-43].
Taken together, we have molecular evidence for auto-
crine PRL signaling in synoviocytes, and our results
suggest that NR4A2 may contribute to synovial hyper-
plasia and inflammation by increasing PRL expression.Discussion
We previously reported that the orphan nuclear receptor
NR4A2 induces cellular changes that contribute to syn-
ovial hyperplasia [10], and we therefore aimed to explore
the underlying molecular mechanisms in the current
study. We conducted a gene expression screen to identify
novel transcriptional targets of NR4A2 in synoviocytes,
and identified the immunomodulatory peptide hormone
PRL as a target of NR4A2. PRL mRNA and protein are
potently induced by ectopic NR4A2 (Figure 2) and en-
dogenous NR4A receptors are required for PRL expres-





























ISG15 + 295-fold 
IL4R + 44-fold 
EPOR + 19-fold 
AKT1 +  2-fold 
BCL2L1 +  2-fold 
C/EBPD +  2-fold 
IRF1 +  2-fold 
IRF9 +  2-fold 
SH2B1 +  2-fold 
SOCS1 +  2-fold 
CDKN1A - 1394-fold 
Figure 6 PRL regulates expression of genes involved in
inflammation, proliferation, and cell survival. A. K4IM
synoviocytes were treated in triplicate with TNF-α (10 ng/mL) or
PGE2 (1 μM) for 24 hours. PRL-R was measured by RT-qPCR.
***p < 0.001. B. cDNA from K4IM synoviocytes treated with rhPRL
(1 μg/mL, 24 hours) was analyzed on JAK/STAT signaling pathway
qPCR arrays. Gene expression data was normalized to 3 housekeeping
genes and the genes most highly regulated by rhPRL are displayed.
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mechanism that requires a functional DNA binding do-
main (Figure 5). Furthermore, NR4A2-induced PRL may
function in an autocrine manner to promote synovial
hyperplasia and inflammation. In support of this, we de-
termined that PRL regulates the expression of a subset ofgenes that contribute to inflammation, proliferation, and
cell survival in inflamed joints (Figure 6). Our results
provide the first evidence for NR4A2 regulation of PRL
transcription in synoviocytes, and highlight a novel tran-
scriptional pathway that may impact inflammatory joint
diseases.
While PRL is primarily secreted from the anterior pi-
tuitary gland with critical functions in lactation and
reproduction, this hormone is also expressed in a num-
ber of extrapituitary sites such as the brain, mammary
gland, and immune system [19]. PRL has numerous
immunomodulatory functions including stimulating
cytokine expression, iNOS production, and T-cell prolif-
eration [19]. In line with this, elevated PRL levels have
been linked to autoimmune disorders such as systemic
lupus erythematosus, systemic sclerosis, and RA [19]. In
patients with RA, high levels of circulating PRL are cor-
related with disease activity and structural damage
[20,21]. PRL is also present in synovial fluid, where levels
are significantly higher in patients with RA versus OA
[20]. Further supporting a role for PRL in arthritis
pathogenesis, the dopamine agonist bromocriptine re-
duces systemic PRL production and has beneficial effects
in patients with RA and in animal models of disease
[22]. While clinical data suggest pathogenic roles for
PRL in inflammatory arthritis, a mechanistic under-
standing of how PRL expression is regulated within in-
flamed joints is lacking.
To our knowledge, this study is the first to describe a
transcriptional mechanism contributing to the expres-
sion of PRL in synoviocytes. However, several studies
conducted in lymphocytes, endometrial stromal cells,
and breast cancer cells provide an overview of PRL tran-
scription in peripheral tissues [30,34,44-47]. Consistent
with these studies, we confirmed that PRL transcription
in synoviocytes is conferred by the activation of an alter-
native distal promoter located approximately 5 kb up-
stream from the start-site of transcription (Figure 4).
Transcription factors such as CREB, CCAAT/enhancer-
binding protein (C/EBP), Pit-1, FOXO1A, AP-1 and Ets
interact with the distal PRL promoter and induce tran-
scription in a cell-type specific manner [29,44-49]. Of
particular interest to the current study, an NR4A2
homolog, NR4A1 (Nur77 / NGFI-B), has recently been
described as an inducer of the distal PRL promoter in
endometrial stromal cells [47].
Through deletional analysis, we mapped the NR4A2
responsive region of the distal PRL promoter to a
238 bp sequence spanning −270 to -32 bp (Figure 5).
NR4A2 appears to interact with this promoter sequence,
since a well-characterized point mutation in the DNA
binding domain (C283G) abrogates transcription. NR4A
target genes can be regulated by receptor binding to
NBRE sequences in promoters [14], however the
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MMP-13 and IL-8 are induced by NR4A2 in syno-
viocytes via NBRE-independent mechanisms [10,13].
While NR4A2 may target a novel cis-element, there is
also evidence that this receptor works in concert with
other transcription factors to regulate gene expression.
For example, IL-8 is potently induced by NR4A2 through
interactions with p65, and MMP-1 is repressed by
NR4A2 via negative interactions with Ets transcription
factors [9,13]. While these protein-protein mechanisms
are likely promoter and cell-type specific, NR4A2 may
employ a similar mechanism on the PRL promoter. The
NR4A2-responsive region of the PRL promoter contains
binding sites for Ets1, Hox, FOXO1A, C/EBPβ, and
NFκB transcription factors [34,48], and NR4A2 may
interact with one or more of these factors to transactivate
the promoter. Alternatively, NR4A2 may act further up-
stream of the PRL promoter by inducing expression of
one of these transcription factors that subsequently
transactivates the PRL promoter.
Within inflamed joints, resident synoviocytes and
chondrocytes, and infiltrating immune cells are equipped
to respond to PRL via activation of cell-surface PRL-R
and intracellular JAK/STAT signaling pathways [23,25,26].
PRL likely mediates its effects in vivo by triggering a com-
bination of autocrine and paracrine responses. Locally
produced PRL can induce synoviocyte proliferation and
upregulate the expression of IL-6, IL-8, and MMP-3 [23].
However, in our experiments, we did not observe these
effects on proliferation or gene expression. Since the pri-
mary synoviocytes used for these experiments were de-
rived from patients with RA, the different responses noted
could be due in part to patient heterogeneity. We did con-
firm PRL-R expression, suggesting that the basic mechan-
ism to respond to PRL was intact in our cells (Figure 6A).
Furthermore, we documented a subset of 11 genes that
are regulated by rhPRL in synoviocytes (Figure 6B).
Importantly, Akt1, IRF1, and SOCS-1 are known tran-
scriptional targets of PRL [36-38], and we demonstrated a
2-fold increase in their expression. In mammary epithelial
cells, PRL induces the phosphorylation of STAT5, which
in turn regulates Akt1 transcription and promotes cell sur-
vival [36]. In synoviocytes from patients with RA, this sig-
naling molecule also plays an important role in cell
survival and proliferation [39,40]. Interferon regulatory
factor-1 (IRF-1) is an immediate-early gene induced by
PRL in T-cells, where it has a regulatory role in cell
growth [37]. Interestingly, IRF-1 is highly expressed in RA
synovial tissue, suggesting an important role for this
factor in disease [42]. The cell cycle inhibitor CDKN1A
(CIP1/p21) was potently suppressed by PRL (1394-fold),
consistent with reduced expression in RA synovial tis-
sue correlating with enhanced synoviocyte migration
and invasion [41]. The most potently induced genes,interferon-induced protein IFI-15 K (ISG15), interleukin
4 receptor (IL4R), and erythropoietin receptor (EPOR)
have not been described previously as PRL target genes,
suggesting that PRL regulates a unique set of genes in
synoviocytes. Taken together, the PRL responsive genes
identified in this experiment contribute to inflamma-
tion, proliferation, and cell survival [36-43]. Based on
these molecular findings, we hypothesize that NR4A2-
induced PRL contributes to synovial hyperplasia and in-
flammatory processes via the regulation of downstream
target genes.
While PRL appears to have autocrine effects on syno-
viocytes, it is also likely that PRL exerts paracrine effects
on other cell-types present in joints. PRL inhibits the
apoptosis of chondrocytes induced by inflammatory cy-
tokines and serum starvation [25,27], suggesting that
PRL may have chondroprotective effects. Furthermore,
PRL induces the growth and chondrogenic differenti-
ation of bone marrow derived mesenchymal stem cells,
supporting a role for this signaling pathway in cartilage
formation and repair [26]. PRL may also target endothe-
lial cells and regulate angiogenesis [50,51], a process that
is enhanced in chronically inflamed joints. However,
PRL can be cleaved into an anti-angiogenic form by
MMPs released from chondrocytes [24], suggesting that
these effects on angiogenesis are tightly regulated. Taken
together, NR4A2-induced PRL may exert multiple effects
in inflamed joints and it will be critical to explore the
in vivo impact of this novel transcriptional pathway in
future studies.
Conclusions
We have identified PRL as a transcriptional target of
NR4A2 in synoviocytes, providing new insight into the
regulation of this gene in extrapituitary sites. Further
investigation of the NR4A2-PRL pathway may lead to
new treatments for inflammatory arthritis. In addition,
the ability to regulate PRL levels with selective NR4A2
antagonists may provide novel approaches to manage
hyperprolactinemia associated with other autoimmune
disorders and conditions.
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